USPTO serial 88490185
AC5-V
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 22, 2020
- Examiner
- RADEMACHER, APRIL LUEDERS
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with AC5-V?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $425
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Yvonne Shyntum
Yvonne Shyntum PABST PATENT GROUP LLP1545 PEACHTREE STREET NE, SUITE 320ATLANTA, GA 30309UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | peptide to manage, stop or prevent the undesirable movement in or on the body, of blood, inflammatory cells, bacteria, and contaminants, and for the treatment of wounds and bleeding / leaking tissue and blood vessels | ACTIVE | Dec 17, 2018 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 22, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Sep 22, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 20, 2020 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Aug 19, 2020 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jul 27, 2020 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jul 25, 2020 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 7, 2020 | IUAF | USE AMENDMENT FILED | — |
| Jul 7, 2020 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jan 7, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 12, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 12, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 23, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 4, 2019 | ALIE | ASSIGNED TO LIE | — |
| Sep 29, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 29, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 29, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 29, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 29, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 17, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 22, 2019 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Jul 22, 2019 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jul 6, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |